` XERS (Xeris Biopharma Holdings Inc) vs S&P 500 Comparison - Alpha Spread

XERS
vs
S&P 500

Over the past 12 months, XERS has significantly outperformed S&P 500, delivering a return of 145% compared to the S&P 500's 8% growth.

Stocks Performance
XERS vs S&P 500

Loading

Performance Gap
XERS vs S&P 500

Loading
XERS
S&P 500
Difference

Performance By Year
XERS vs S&P 500

Loading
XERS
S&P 500
Add Stock

Competitors Performance
Xeris Biopharma Holdings Inc vs Peers

S&P 500
XERS
LLY
JNJ
NOVO B
ROG
Add Stock

Xeris Biopharma Holdings Inc
Glance View

Market Cap
639.6m USD
Industry
Pharmaceuticals

Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

XERS Intrinsic Value
4.91 USD
Undervaluation 13%
Intrinsic Value
Price
Back to Top